Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin

摘要: Pseudomonas aeruginosa (PsA) is a highly prevalent bacterial organism recovered from the lungs of cystic fibrosis (CF) patients and chronic PsA infection linked to progressive pulmonary function decline. The eradication treatment this CF airways particularly challenging care providers. Aerosolized antibiotics that target help slow down growth, maintain lung reduce frequency exacerbations. In review, we discuss currently available inhaled for management infections in patients, with focus on liposomal amikacin inhalation (LAI). LAI unique formulation under development enhances drug delivery retention via incorporation into neutral liposomes. Factors such as once-daily dosing, mucus biofilm penetration potentially prolonged off-drug periods make attractive option manage patients.